IWWM-10 Posters: W40 - W79

The following abstracts represent Posters W40-W79 that were presented at IWWM-10 (NYC-2018) Poster Session. "ORAL" signifies a 10-minute oral presentation was given during the poster session.

Session Chairs: Ranjana Advani (USA) and Marvin Stone (USA)

W40: Preclinical Activity of IRAK4 Kinase Inhibitor CA-4948 Alone or in Combination with Targeted Therapies in Non-Hodgkin Lymphoma R. Booher, USA

W41: Therapeutic disruption of Bcl-2 in Conjunction with blocking CD38 results in mitochondrial collapse and apoptosis of Waldenström Macroglobulinemia tumor cells S. Ahmed, USA

W42: High-Dose Therapy and Stem Cell Transplantation in Transformed Waldenstrom Macroglobulinemia E. Durot, France

W43: CANOMAD: clinical, biological, electrophysiological and treatment analyses in 44 patients. A French retrospective study of the FILO group M. Le Cann, France

W44: Waldenström's Macroglobulinemia (WM) Clinical Trials in the United States (U.S.0: Characteristics and Disparities Over Two Decades P. Jani, USA

W45: Structurally novel curcumin analogs show tumor-specific cytoxicity in preclinical models of Waldenström Macroglobulinemia M. Iqbal, USA

W46: Dual-affinity BTK/PI3Ky overcome ibrutinib-resistance in preclinical models of Waldenstrom Macroglobulinemia M. Iqbal, USA

W47: CXCR4 mutations have no survival impact on Waldenstrom's Macroglobulinemia patients under Bortezomib-based treatment R. Sklavenitis-Pistofidis, USA

W48: Ibrutinib decreases the apoptotic threshold of Waldenström macroglobulinemia (WM) cells rendering them vulnerable to venetoclax A Manna, USA

W49: Concurrent targeting of the proteasome (ixazomib) and BTK (ibrutinib) is highly toxic inducing apoptosis through mitochondrial disruption and Bcl-2/BCR downregulation in Waldenström Macroglobulinemia cells A Manna, USA

W50: Targeting IRAK4 and PI3Kα/δ induces synergistic cell death in ibrutinib-resistant Waldenström macroglobulinemia cells A Manna, USA

W51: Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: outcomes outside of clinical trial setting J. Abeykoon, USA

W52: Clinical presentation and Outcome of Patients with Myeloid Differentiation Factor 88 Gene (MYD88) Wild-Type Waldenström Macroglobulinemia J. Abeykoon, USA

W53: A novel patient-derived xenograft (PDX) model of Richter's transformed Waldenström macroglobulinemia A Sonikpreet, USA

W54: Pre-clinical high-throughput drug screening identifies novel therapeutics in Ibrutinib-resistant Bing-Neel cells A Sonikpreet, USA

W55: Development of pre-clinical model of Bing-Neel syndrome A Sonikpreet, USA

W56: Dual targeting of B5 and B1i-proteasome catalytic sub-unites is lethal to Waldenstrom macroglobulinemia cells: Therapeutic implication through novel drug candidates S. Akhtar, USA

W57: Restructuring Bcl-2 family protein interactions to overcome deferred apoptosis in Waldenstrom macroglobulinemia tumor cells: A novel role for targeting Mcl-1 A Sharma, USA

W58: IgM associated Light Chain (AL) Amyloidosis: Clinical, Genomic and Bone Marrow Pathology Features S. Sidana, USA

W59: Sustained efficacy of Ibrutinib over 30 months in Bing-Neel Syndrome E. Hatjiharissi, Greece

W60: Histological transformation in Waldenström macroglobulinemia S. Zanwar, USA

W61: Bing Neel Syndrome in Waldenström macroglobulinemia S. Zanwar, USA

W62: Waldenström macroglobulinemia with excess plasma cells: Is it a distinct entity? S. Zanwar, USA

W64: Ibrutinib for the treatment of Bing Neel Syndrome G. Itchaki, Israel

W65: The impact of CXCR4 mutation subtypes in the response and progression-free survival of patients with Waldenstrom macroglobulinemia treated with ibrutinib J. Castillo, USA

W66: Low Levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with Waldenström macroglobulinemia J. Castillo, USA

W67: Ibrutinib Withdrawal Symptoms in Patients with Waldenström Macroglobulinemia J. Castillo, USA

W68: Low Risk of pneumocystis jiroveci Pneumonia in Patients with Waldenstrom Macroglobulinemia on Ibrutinib M. Cheng, USA

W69: Survival Rates and Clinical Characteristics of Young Patients with Waldenström Macroglobulinemia A Babwah, USA

W70: Evidence for clonal cooperativity in BTK Cys481Ser driven Ibrutinib resistance in Waldenström's Macroglobulinemia J. Chen, USA

W71: Mutated MYD88 cross-talk to BCR signaling through activating SYK kinase in Waldenström's Macroglobulinemia M. Munshi, USA

W72: Histological transformation in WM/LPL: absence of MYC rearrangements and rare clonally unrelated events R. Owen, United Kingdom

W73 ORAL: Significance of residual neoplastic B-cells by flow cytometry following treatment in the R2W trial R. de Tute, United Kingdom

W74: Impaired plasma cell differentiation on Waldenstrom macroglobulinemia B-cells following TLR stimulation J. Shrimpton, United Kingdom

W75: Dysregulation of B-Cell Receptor Pathway Genes Through Alternative Splicing in Waldenstrom's Macroglobulinemia N. Tsakmaklis, USA

W76: Alternative Mutations and Isoform Dysregulation in MYD88 Waldenstrom's Macroglobulinemia A Kofides, USA

W77: Comparative genomic analysis of Waldenstrom's macroglobulinemia cell lines G. Chan, USA

W78: TIR8 (SIGIRR) is suppressed in WM, and may contribute to MYD88/TLR pro-survival signaling in WM M. Demos, USA

W79: Deregulated expression of PTBPs are associated with altered splicing in Myeloma (MM) and Waldenstrom's macroglobulinemia (WM) S. Adamia, USA